Alzheimer’s Research & Therapy (Apr 2021)

Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

  • James D. Doecke,
  • Cindy Francois,
  • Christopher J. Fowler,
  • Erik Stoops,
  • Pierrick Bourgeat,
  • Stephanie R. Rainey-Smith,
  • Qiao-Xin Li,
  • Colin L. Masters,
  • Ralph N. Martins,
  • Victor L. Villemagne,
  • Steven J. Collins,
  • Hugo Marcel Vanderstichele

DOI
https://doi.org/10.1186/s13195-021-00812-9
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration. Methods Biomarkers for β-amyloidopathy (Aβ1–42, Aβ1–40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, α-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer’s disease, N = 6). Results High biomarker concordance between extraction methods was seen (concordance correlation > 0.85). Passing Bablock regression defined low beta coefficients indicating high scalability. Conclusions Levels of these commonly assessed CSF biomarkers are not influenced by extraction method. Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.

Keywords